Oncology Drugs

A coalition of top GOP senators and state attorneys general is urging the FDA to pull mifepristone, escalating the fight over abortion to the federal level.

The AI health-tech leader achieved profitability and massive growth in 2025, expanding its reach to nearly 2,000 hospitals and doubling its life sciences arm.

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

Following a successful three-year transformation, B-FLEXION acquires full ownership of Radius Health, betting big on its blockbuster osteoporosis drug TYMLOS®.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

New clinical data suggests a more convenient option for cancer patients, potentially eliminating a return trip to the clinic for a key supportive care drug.

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

As part of a $23B US investment, Novartis will build a cutting-edge facility in Winter Park, cementing Florida’s role in advanced cancer treatment.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.